KRYS — Krystal Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- $7.09bn
- $6.41bn
- $290.52m
- 86
- 20
- 96
- 76
Annual cashflow statement for Krystal Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -32.2 | -69.6 | -140 | 10.9 | 89.2 |
| Depreciation | |||||
| Non-Cash Items | 3.31 | 16.8 | 32.5 | 33.1 | 42.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.928 | 2.05 | 2.81 | -138 | -14.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -26.1 | -47.9 | -101 | -88.8 | 123 |
| Capital Expenditures | -14.8 | -68.3 | -53 | -11.8 | -4.24 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 3.66 | -158 | -61.1 | 94.4 | -159 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -11.2 | -227 | -114 | 82.6 | -163 |
| Financing Cash Flow Items | — | -7.96 | -0.649 | -0.749 | -5.39 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 118 | 348 | 35.3 | 203 | 27 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 80.8 | 73 | -179 | 196 | -13.5 |